rVIIa
Showing 1 - 10 of 10
Hemophilia A Trial in Metairie, New Orleans (Factor IX)
Recruiting
- Hemophilia A
- Factor IX
-
Metairie, Louisiana
- +1 more
Nov 14, 2022
Hemophilia A With Inhibitors, Hemophilia B With Inhibitors Trial in Worldwide (CSL689, Eptacog alfa (activated))
Terminated
- Hemophilia A With Inhibitors
- Hemophilia B With Inhibitors
- CSL689
- Eptacog alfa (activated)
-
Tbilisi, Georgia
- +9 more
Aug 27, 2019
Severe Bleeding, Urgent Surgery Trial (Urgent surgery which can not be postponed to the next 24 hrs)
Withdrawn
- Severe Bleeding
- Urgent Surgery
- Urgent surgery which can not be postponed to the next 24 hrs
- (no location specified)
Jul 15, 2020
Healthy Trial in Berlin (rVIIa-FP, Placebo (0.9% normal saline))
Completed
- Healthy
- rVIIa-FP
- Placebo (0.9% normal saline)
-
Berlin, GermanyPhase I Unit
Apr 19, 2017
Congenital Coagulation Factor VII Deficiency Trial in Njmegen, Oslo (Eptacog alfa (activated) or pdFVII, CSL689)
Completed
- Congenital Coagulation Factor VII Deficiency
- Eptacog alfa (activated) or pdFVII
- CSL689
-
Njmegen, Netherlands
- +1 more
Apr 25, 2017
Coagulopathy During Cardiac Surgery Trial in Austria, Germany (Conventional laboratory testing (Central laboratory), POC
Unknown status
- Coagulopathy During Cardiac Surgery
- Conventional laboratory testing (Central laboratory)
- POC testing
-
Linz, Oberösterreich, Austria
- +3 more
May 3, 2017
rFVIIa (Novoseven) in Haemorrhagic Traumatology
Completed
- Hemorrhage
- Bleeding
- observational study
-
Alencon, France
- +38 more
Nov 17, 2014
Acquired Bleeding Disorder, Trauma Trial in Worldwide (eptacog alfa (activated), )
Terminated
- Acquired Bleeding Disorder
- Trauma
- eptacog alfa (activated)
- placebo
-
Princeton, New Jersey
- +13 more
Jun 13, 2014
Myocardial Ischemia, Blood Coagulation Disorders, Coronary Artery Disease Trial in Melbourne (Recombinant Activated Factor VII)
Unknown status
- Myocardial Ischemia
- +3 more
- Recombinant Activated Factor VII
-
Melbourne, Victoria, AustraliaAustin Health
Sep 14, 2005